{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:38:50Z","timestamp":1780472330827,"version":"3.54.1"},"reference-count":43,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Women's Health"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Bremelanotide, a melanocortin receptor agonist, is Food and Drug Administration (FDA)-approved for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Review of bremelanotide's safety profile from the clinical development program (phases 1 through 3).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The clinical development program comprised 3500 subjects in 43 completed studies. In the phase 3 studies, subjects took bremelanotide for up to 18 months. The most common adverse events (AEs) were nausea (40.0% vs. 1.3%), flushing (20.3% vs. 1.3%), headache (11.3% vs. 1.9%), and injection site reactions (5.4 vs. 0.5), bremelanotide versus placebo groups, respectively, in the integrated double-blind portion of the phase 3 studies (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u20091247). Nausea was the most common reason for bremelanotide discontinuation. There were no deaths; a few subjects experienced serious AEs. Focal hyperpigmentation was rare when bremelanotide was dosed in accordance with label recommendations, but it occurred in more than one-third of subjects following up to 16 consecutive daily dosings. Small and transient but statistically significant blood pressure increases were observed during ambulatory blood pressure monitoring. Most drug\u2013drug interactions were not clinically significant, except for interactions that lowered plasma concentrations of indomethacin and naltrexone. In the double-blind portion of the integrated phase 3 studies, 70% of the bremelanotide group proceeded to the open-label phase of the studies versus 87% of those on placebo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The AEs associated with bremelanotide are mostly mild to moderate. Although not deemed clinically important, bremelanotide should be used with caution in patients at risk of cardiovascular disease, and blood pressure should be well controlled during treatment. Clinical Trial Registration number: NCT02333071 [Study 301] and NCT02338960 [Study 302].<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jwh.2021.0191","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T11:14:40Z","timestamp":1644578080000},"page":"171-182","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Safety Profile of Bremelanotide Across the Clinical Development Program"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4372-0879","authenticated-orcid":false,"given":"Anita H.","family":"Clayton","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, Virginia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl A.","family":"Kingsberg","sequence":"additional","affiliation":[{"name":"Department of Reproductive Biology and Department of Psychiatry, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Portman","sequence":"additional","affiliation":[{"name":"Sermonix Pharmaceuticals, Columbus, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amama","family":"Sadiq","sequence":"additional","affiliation":[{"name":"AMAG Pharmaceuticals, Inc., Waltham, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Krop","sequence":"additional","affiliation":[{"name":"AMAG Pharmaceuticals, Inc., Waltham, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jordan","sequence":"additional","affiliation":[{"name":"Palatin Technologies, Inc., Cranbury, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johna","family":"Lucas","sequence":"additional","affiliation":[{"name":"Palatin Technologies, Inc., Cranbury, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Simon","sequence":"additional","affiliation":[{"name":"George Washington University and IntimMedicine\u2122 Specialists, Washington, District of Columbia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181898cdb"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2009.01252.x"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esxm.2018.01.004"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2010.04.010"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/14681990120040078"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/009262301750257119"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.01.035"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brat.2014.04.001"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/14681994.2015.1127909"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/jsm.13056"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/1755-7682-6-37"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.09.018"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.v06n0403"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/009262301750257155"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000125686.20338.c1"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199906000-00012"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0288-1"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071705"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.4155\/cli.12.18"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389203717666160226145330"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2006-0034"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0400491101"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2009.01309.x"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.10bs06115whi"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1080\/00224490902747222"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2008.01177.x"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2010.02032.x"},{"key":"e_1_3_6_29_2","unstructured":"Addyi (flibanserin) [prescribing information]. Raleigh NC: Sprout Pharmaceuticals 2019."},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2003.tb03167.x"},{"key":"e_1_3_6_31_2","unstructured":"Vyleesi (bremelanotide) [prescribing information]. Cranbury NJ: Palatin Technologies Inc. 2020."},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2007.00610.x"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000003500"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000003514"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.2217\/whe-2016-0018"},{"key":"e_1_3_6_36_2","doi-asserted-by":"crossref","unstructured":"White WB Portman D Faught B Viswanathan B Williams L Krop J. Effect of bremelanotide on ambulatory blood pressure when administered for up to 16 consecutive days. Paper presented at: 69th 2020 ACOG Annual Clinical and Scientific Meeting; Seattle WA 2020.","DOI":"10.1097\/01.AOG.0000663136.08259.60"},{"key":"e_1_3_6_37_2","unstructured":"Pesco-Koplowitz L Koplowitz B Kornstein S Jordan R Lucas J. Pharmacokinetics of the coadministration of bremelanotide and norethindrone\/ethinyl estradiol oral contraceptives: A phase 1 randomized double-blind placebo-controlled trial. Paper presented at: American College of Clinical Pharmacology; Seattle WA 2018."},{"key":"e_1_3_6_38_2","unstructured":"Pesco-Koplowitz L Koplowitz B Jordan R Lucas J. Pharmacokinetics of the coadministration of bremelanotide and metformin: A phase 1 randomized double-blind placebo-controlled trial. Paper presented at: American College of Clinical Pharmacy; Seattle WA 2018."},{"key":"e_1_3_6_39_2","unstructured":"Pesco-Koplowitz L Koplowitz B Clayton A Lucas J Jorda R Sadiq A. A phase 1 crossover study of bremelanotide coadministered with venlafaxine sertraline or naltrexone\/bupropion in healthy female subjects. Accepted at: American Psychiatric Association 2020 Annual Meeting; Philadelphia PA 2020. Virtual presentation."},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.01.018"},{"key":"e_1_3_6_41_2","unstructured":"MacDougall MR Sharma S. Physiology chemoreceptor trigger zone. StatPearls 2020. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537133\/#_NBK537133_pubdet Accessed June16 2021."},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2016.00095"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2020.8460"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001221"}],"container-title":["Journal of Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jwh.2021.0191","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jwh.2021.0191","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jwh.2021.0191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:55:27Z","timestamp":1777658127000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jwh.2021.0191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1089\/jwh.2021.0191"],"URL":"https:\/\/doi.org\/10.1089\/jwh.2021.0191","relation":{},"ISSN":["1540-9996","1931-843X"],"issn-type":[{"value":"1540-9996","type":"print"},{"value":"1931-843X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}